The rise of Sildenafil initially fueled a period of growth for major pharmaceutical companies, however recent shifts present a murky outlook for shareholders. Lower-cost versions are eroding revenue, and continued https://nikolaseprm407835.blogthisbiz.com/48882601/viagra-and-pharma-a-volatile-investment